MARKET

DRRX

DRRX

DURECT
NASDAQ
6.41
-0.16
-2.44%
Closed 16:00 01/30 EST
OPEN
6.52
PREV CLOSE
6.57
HIGH
6.61
LOW
6.39
VOLUME
25.59K
TURNOVER
105.62K
52 WEEK HIGH
9.70
52 WEEK LOW
3.165
MARKET CAP
146.06M
P/E (TTM)
-45.7857
1D
5D
1M
3M
1Y
5Y
5 Most Expensive Health Care Stocks You Should Worry About
Benzinga · 01/12 14:01
On December 20, 2022, Durect Corp. Received A Letter From Nasdaq That Co Has Regained Compliance For Continued Listing On Nasdaq
Benzinga · 12/20/2022 21:34
Oppenheimer Maintains Outperform on Durect, Adjusts Price Target to $32 - 1-for-10 Reverse Stock Split
Benzinga · 12/07/2022 11:21
--Oppenheimer Adjusts Price Target on Durect to $32 From $6 on Reverse Stock Split, Market Conditions, Maintains Outperform Rating
--Oppenheimer Adjusts Price Target on Durect to $32 From $6 on Reverse Stock Split, Market Conditions, Maintains Outperform Rating
MT Newswires · 12/07/2022 09:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/29/2022 13:08
Reported Late Monday, DURECT Corp. Announces 1-For-10 Reverse Stock Split
Benzinga · 11/29/2022 06:32
DURECT to Implement 1-for-10 Reverse Stock Split
DURECT to Implement 1-for-10 Reverse Stock Split
MT Newswires · 11/29/2022 03:53
Durect GAAP EPS of -$0.01 in-line, revenue of $11.98M misses by $1.01M
Seekingalpha · 11/02/2022 20:18
More
About DRRX
DURECT Corporation is a biopharmaceutical company that is focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The Company is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with severe alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The Company focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug.

Webull offers kinds of DURECT Corp stock information, including NASDAQ:DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.